{"title":"Retroperitoneal Myoepithelial Carcinoma: A Case Report and Literature Review.","authors":"Tong Wei, Hongmin Quan, Rengui Wang, Xiaoli Sun","doi":"10.2147/CMAR.S494121","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Myoepithelial carcinoma is rare, and myoepithelial carcinoma occurring outside the head and neck is even rarer. We reported one case of retroperitoneal myoepithelial carcinoma.</p><p><strong>Case summary: </strong>A 63-year-old woman who underwent computed tomography (CT) for progressive abdominal distension revealed a left retroperitoneal mass and subsequently underwent surgical treatment where the mass was completely removed with a postoperative diagnosis of retroperitoneal myoepithelial carcinoma. A follow-up CT review 40 days after surgery revealed a recurrence of the mass. After 8 months of chemotherapy and targeted immunotherapy, a follow-up review of the CT images revealed a gradual reduction in the mass. Four months after the cessation of chemotherapy and targeted drug combined immunotherapy, a follow-up review via CT revealed another recurrence and enlargement of the mass.</p><p><strong>Conclusion: </strong>CT of retroperitoneal myoepithelial carcinoma revealed a massive cystic solid mass in the abdominal cavity and retroperitoneum. The solid region of the mass was significantly enhanced and the cystic region was without enhancement on enhanced CT; the mass involved the adjacent duodenum, partial jejunum, and left renal vein. PET‒CT imaging revealed hypermetabolism in the solid region of the mass and no hypermetabolism in the cystic region.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"617-624"},"PeriodicalIF":2.6000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11928755/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Management and Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/CMAR.S494121","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Myoepithelial carcinoma is rare, and myoepithelial carcinoma occurring outside the head and neck is even rarer. We reported one case of retroperitoneal myoepithelial carcinoma.
Case summary: A 63-year-old woman who underwent computed tomography (CT) for progressive abdominal distension revealed a left retroperitoneal mass and subsequently underwent surgical treatment where the mass was completely removed with a postoperative diagnosis of retroperitoneal myoepithelial carcinoma. A follow-up CT review 40 days after surgery revealed a recurrence of the mass. After 8 months of chemotherapy and targeted immunotherapy, a follow-up review of the CT images revealed a gradual reduction in the mass. Four months after the cessation of chemotherapy and targeted drug combined immunotherapy, a follow-up review via CT revealed another recurrence and enlargement of the mass.
Conclusion: CT of retroperitoneal myoepithelial carcinoma revealed a massive cystic solid mass in the abdominal cavity and retroperitoneum. The solid region of the mass was significantly enhanced and the cystic region was without enhancement on enhanced CT; the mass involved the adjacent duodenum, partial jejunum, and left renal vein. PET‒CT imaging revealed hypermetabolism in the solid region of the mass and no hypermetabolism in the cystic region.
期刊介绍：
Cancer Management and Research is an international, peer reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for cancer patients. Specific topics covered in the journal include:
◦Epidemiology, detection and screening
◦Cellular research and biomarkers
◦Identification of biotargets and agents with novel mechanisms of action
◦Optimal clinical use of existing anticancer agents, including combination therapies
◦Radiation and surgery
◦Palliative care
◦Patient adherence, quality of life, satisfaction
The journal welcomes submitted papers covering original research, basic science, clinical & epidemiological studies, reviews & evaluations, guidelines, expert opinion and commentary, and case series that shed novel insights on a disease or disease subtype.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
